Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$93.78

0.34 (0.36%)

, AZN

AstraZeneca

$38.68

0.84 (2.22%)

04:55
09/26/18
09/26
04:55
09/26/18
04:55

International Association for Study of Lung Cancer

19th World Conference on Lung Cancer will be held in Toronto, Canada on September 23-26.

ABBV

AbbVie

$93.78

0.34 (0.36%)

AZN

AstraZeneca

$38.68

0.84 (2.22%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$61.82

0.24 (0.39%)

CELG

Celgene

$87.56

-0.01 (-0.01%)

LOXO

Loxo Oncology

$166.80

3.73 (2.29%)

MRK

Merck

$70.65

-0.16 (-0.23%)

NEO

NeoGenomics

$14.93

0.39 (2.68%)

NVCR

Novocure

$50.80

1.95 (3.99%)

NVS

Novartis

$85.88

0.6 (0.70%)

PFE

Pfizer

$43.80

-0.13 (-0.30%)

SPPI

Spectrum

$17.12

0.59 (3.57%)

RHHBY

Roche

$0.00

(0.00%)

TKPYY

Use TAK

$0.00

(0.00%)

TMO

Thermo Fisher

$243.18

1.03 (0.43%)

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 29

    Sep

  • 01

    Oct

  • 03

    Oct

  • 03

    Oct

  • 03

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 26

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

ABBV AbbVie
$93.78

0.34 (0.36%)

09/10/18
BTIG
09/10/18
INITIATION
Target $32
BTIG
Buy
Voyager Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed Voyager Therapeutics (VYGR) with a Buy rating and a price target of $32, saying the company is an "attractive investment" based on its lead product for late-stage Parkinson's Disease patients and its "robust" adeno-associated viral technology platform. The analyst expects Voyager to be well served in its upcoming gene therapy market share competition and also cites the company's "productive FDA meetings"and the start of of a phase 2 trial. Shrader further notes that Voyager Therapeutics' latest Abbvie (ABBV) deal is a "vote of confidence" for its program.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.
09/19/18
FBCO
09/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's California lawsuit may have broader implications, says Credit Suisse
After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
AZN AstraZeneca
$38.68

0.84 (2.22%)

09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
BAYRY Bayer
$0.00

(0.00%)

09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
BMY Bristol-Myers
$61.82

0.24 (0.39%)

08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
ATLE
08/08/18
UPGRADE
ATLE
Neutral
Bristol-Myers upgraded to Neutral from Underweight at Atlantic Equities
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
CELG Celgene
$87.56

-0.01 (-0.01%)

08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.
09/06/18
ADAM
09/06/18
NO CHANGE
Target $90
ADAM
Buy
Agios ending AG-881 collaboration 'both positive and negative,' says Canaccord
While Celgene's (CELG) termination of the AG-881 collaboration may "suggest some lack of enthusiasm," it does give full rights back to Agios (AGIO), said Canaccord analyst John Newman, who believes "it is almost always better for a smaller biotech to have full commercial control of an asset." The analyst also noted that Jacqualyn Fouse is expected to assume the CEO role next February and Newman believes she will help maintain Agios' heading in launching approved products and developing the pipeline. Newman maintains a Buy rating and $90 price target on Agios shares.
09/20/18
HCWC
09/20/18
NO CHANGE
Target $2
HCWC
Neutral
OncoMed price target lowered to $2 after Celgene pass at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target on OncoMed (OMED) shares to $2 from $3 after partner Celgene (CELG) passed on its option to license navicixizumab. Worldwide development, commercialization and rights to navicixizumab now remain under OncoMed's control while Celgene retains options to license OncoMed's anti-TIGIT monoclonal antibody, etigilimab, and anti-RSPO3, rosmantuzumab, noted White. The analyst, who notes there is potential the company could partner the asset, keeps a Neutral rating on OncoMed shares.
LOXO Loxo Oncology
$166.80

3.73 (2.29%)

08/13/18
SBSH
08/13/18
NO CHANGE
Target $235
SBSH
Buy
Citi opens 90-day positive catalyst watch for Loxo Oncology
Citi analyst Yigal Nochomovitz opened a 90-day positive catalyst watch for Loxo Oncology in anticipation of updated duration of therapy data for lead asset larotrectinib at the European Society for Medical Oncology meeting in October. The analyst is expecting positive data, meaning increased average duration of at least six months, and sees the stock up 15%-20% on the news. He has a Buy rating on Loxo shares with a $235 price target.
09/17/18
GSCO
09/17/18
INITIATION
Target $165
GSCO
Neutral
Loxo Oncology initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi started Loxo Oncology with a Neutral rating and $165 price target. The analyst views the stock's risk/reward profile as balanced and he struggles "to find material upside" for the name. Choi initiated coverage of the smid-cap biotech sector with a Neutral coverage view. He views sector fundamentals as healthy but says high valuations temper his enthusiasm.
09/17/18
GUGG
09/17/18
INITIATION
Target $184
GUGG
Neutral
Loxo Oncology initiated with a Neutral at Guggenheim
Target $184.
09/24/18
LEER
09/24/18
INITIATION
Target $205
LEER
Outperform
Loxo Oncology initiated with an Outperform at Leerink
Leerink analyst Andrew Berens started Loxo Oncology with an Outperform rating and $205 price target.
MRK Merck
$70.65

-0.16 (-0.23%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
NEO NeoGenomics
$14.93

0.39 (2.68%)

09/18/18
FANA
09/18/18
NO CHANGE
Target $16
FANA
Outperform
NeoGenomics price target raised to $16 from $14 at First Analysis
First Analysis analyst Joseph Munda raised his price target for NeoGenomics to $16 following meetings with management. The analyst now has reinforced confidence that the company's "one-stop oncology testing shop" remains well positioned to scale its pharma services business and to continue to take clinical testing market share. He keeps an Outperform rating on NeoGenomics.
08/21/18
LEER
08/21/18
INITIATION
Target $18
LEER
Outperform
NeoGenomics initiated with an Outperform at Leerink
Leerink analyst Puneet Souda started NeoGenomics with an Outperform rating and $18 price target. The analyst believes the company is a "uniquely" positioned one-stop shop oncology testing service provider with faster turnaround times versus its competition and a tech-only model that has helped it grow to the current levels. Souda projects NeoGenomics to deliver a 13% sales CAGR and about 25% adjusted EBITDA growth over the longer-term.
04/16/18
BTIG
04/16/18
UPGRADE
Target $11
BTIG
Buy
NeoGenomics upgraded to Buy at BTIG on solid volume trends and cost cuts
As reported earlier, BTIG analyst Sean Lavin upgraded NeoGenomics to Buy from Hold with a price target of $11. Lavin says the issues around exposure to Texas and Florida markets as well as lingering issues around Clarient have "largely dissipated". While the analyst remains concerned about the risk of "unexpected reimbursement changes", he adds that Medicare pricing for 2018 being in place cushions the risk around NeoGenomics guidance, while its growing Biopharma business and cost-cutting provide higher growth potential for the stock over time.
05/02/18
FANA
05/02/18
DOWNGRADE
Target $11
FANA
Equal-Weight
NeoGenomics downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Joseph Munda downgraded NeoGenomics to Equal-Weight citing valuation following the company's Q1 results. The analyst says NeoGenomics' fundamentals remain attractive. He has an $11 price target for the shares.
NVCR Novocure
$50.80

1.95 (3.99%)

09/25/18
MZHO
09/25/18
NO CHANGE
Target $58
MZHO
Buy
Novocure shares attractive at current levels, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Novocure with a $58 price target after hosting meetings with management. The analyst believes "significant growth" remains for NovoCure over time as the Optune technology is applied in multiple solid cancer indications. The shares are attractive at current levels relative to the company's growth opportunity, Yang tells investors in a research note.
09/19/18
WELS
09/19/18
NO CHANGE
Target $58
WELS
Outperform
Novocure price target raised to $58 from $53 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Novocure to $58 ahead of the company's September 25 data presentation from the Phase 2 Stellar study of Optune for mesothelioma. Positive top-line data already disclosed by Novocure shows that Optune added to current standard of care improves survival in mesothelioma patients, Biegelsen tells investors in a research note. The analyst expects FDA approval in 2019 and keeps an Outperform rating on shares of Novocure.
09/20/18
DBAB
09/20/18
NO CHANGE
Target $44
DBAB
Hold
Novocure price target raised to $44 from $31 at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert raised his price target for Novocure to $44 after adjusting his model to reflect added patient-based models for GBM outside the U.S. and preliminary assumptions for the recent China collaboration. The analyst, however, keeps a Hold rating on the shares as he does not believe the risk/reward over the next 12 months is "sufficiently positive" to justify a Buy at current levels. Nonetheless, Gilbert continues to believe that "significant upside" is possible over few years if Phase 3 read-outs in larger tumor types are positive.
09/07/18
WEDB
09/07/18
NO CHANGE
Target $50
WEDB
Outperform
Novocure price target raised to $50 from $40 at Wedbush
Wedbush analyst David Nierengarten reiterated an Outperform rating on Novocure and raised his price target to $50 from $40 following positive topline results from the registrational Phase 2 STELLAR trial, which evaluated tumor treating fields on top of standard of care chemotherapy in patients with malignant pleural mesothelioma. In a research note to investors, the analyst says he believes the data, which includes a median OS of 18.2 months compared to 12.1 months historical control and an improvement in progression free survival, could provide a read-through to Novocure's other solid tumor programs. Novocure will present final STELLAR results at the IASLC World Conference on Lung Cancer meeting on September 25, he notes.
NVS Novartis
$85.88

0.6 (0.70%)

09/11/18
09/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Canaccord with analyst Camilo Lyon saying he believes Nike has regained its footing and is marching back to form following two years of a soft product cycle, margin compression, and market share declines. 2. Novartis (NVS) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at Exane BNP Paribas. 3. Darden (DRI) upgraded to Buy from Neutral at Goldman Sachs while Bloomin' Brands (BLMN) was upgraded to Neutral from Sell. 4. South Jersey Industries (SJI) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company's "superior" growth potential is coming into focus while its shares trade at a discount to peers. 5. Snap (SNAP) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter noting that decelerating growth trends, fierce competition for user mindshare and advertiser dollars, and a history of being hugely unprofitable have kept him on the sidelines, but recent management changes and improved execution have led him to update his outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/11/18
SBSH
09/11/18
UPGRADE
SBSH
Buy
Novartis upgraded to Buy from Neutral at Citi
Citi upgraded Novartis to Buy from Neutral. Exane BNP Paribas also upgraded the shares this morning to Neutral.
PFE Pfizer
$43.80

-0.13 (-0.30%)

09/06/18
BMOC
09/06/18
NO CHANGE
Target $47
BMOC
Outperform
Pfizer price target raised to $47 from $44 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Pfizer to $47 and kept his Outperform rating, citing the company's Tafamidis potential prospects of $3.5B or more in sales by 2027. The analyst notes that Transthyretin Amyloid Cardiomyopathy, or ATTR-CM, is a "fatal, under-diagnosed heart disease with no approved treatments", but the new method of diagnosis could ramp up from 1% to 20%, supporting the "robust efficacy" with "benign safety" offered by the company's treatment. Arfaei further contends that Pfizer's 3.5% dividend yield and 14-times forward earnings multiple make the stock attractive.
09/11/18
BARD
09/11/18
NO CHANGE
Target $85
BARD
Outperform
Exact Sciences price target raised to $85 from $74 at Baird
Baird analyst Catherine Ramsey Schulte raised her price target on Exact Sciences (EXAS) to $85 from $74 citing increased confidence in its partnership with Pfizer (PFE). She sees several different potential outcomes given different assumptions for Pfizer rep productivity and order rate increases. Schulte reiterated her Outperform rating on Exact Sciences shares.
09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
SPPI Spectrum
$17.12

0.59 (3.57%)

09/06/18
JEFF
09/06/18
NO CHANGE
Target $25
JEFF
Buy
Spectrum should begin to retrace last week's selloff, says Jefferies
Jefferies analyst Matthew Andrews says the new interim poziotinib data from the MD Anderson Phase 2 non-small cell lung cancer study "don't disappoint." Shares of Spectrum Pharmaceuticals should begin to retrace the drop since last week amid concerns about the Korean poziotinib HER2 data, Andrews tells investors in a research note. The analyst believes the unconfirmed overall response rate of 58% in EGFR and 50% in HER2 are "impressive." He keeps a Buy rating on Spectrum with a $25 price target.
08/31/18
RILY
08/31/18
NO CHANGE
Target $35
RILY
Buy
Spectrum price target raised to $35 from $26 at B. Riley FBR
B. Riley FBR analyst David Buck raised his price target for Spectrum Pharmaceuticals to $36 and keeps a Buy rating on the shares ahead of the company's September 5 data abstract.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $40
HCWC
Buy
Spectrum price target raised to $40 from $34 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Spectrum Pharmaceuticals to $40 after the company presented at his firm's conference. The analyst remains optimistic about both the stock and the company's pipeline, which he notes includes poziotinib in non-small cell lung cancer and HER2-positive breast cancer and Rolontis in chemotherapy-induced neutropenia. Progress is being made across developmental programs along with upcoming catalysts, White tells investors in a research note. He keeps a Buy rating on Spectrum.
06/27/18
RILY
06/27/18
NO CHANGE
Target $26
RILY
Buy
Spectrum takeover report 'plausible,' says B. Riley FBR
Following a report from Bloomberg yesterday that Spectrum Pharmaceuticals is exploring options including a sale of the business amid takeover interest from other drugmakers, B. RIley FBR analyst David Buck told investors in a research note that while he has no confirmation of any takeover interest or sale process, he sees the report as "plausible." Buck, who reiterated a Buy rating, says that he continues to see his $26 per share target based on DCF and 2022E earnings power as "reasonable." Aide from any actual news on a potential transaction or sales process that gets confirmed, he expects further news flow on pipeline drug Rolontis, including a June 29 Spectrum-sponsored conference call and an expected presentation of additional poziotinib data at the World Lung Conference.
RHHBY Roche
$0.00

(0.00%)

09/13/18
CANT
09/13/18
NO CHANGE
Target $36
CANT
Overweight
Cantor boosts Corbus target to Street-high $36 after Roche study 'fell short'
Cantor Fitzgerald analyst Elemer Piros raised his price target for Corbus Pharmaceuticals to a Street-high $36 following abstracts from the American College of Rheumatology meeting, which is taking place in October. Among the abstracts, Phase 3 data from Roche's (RHHBY) Phase 3 systemic sclerosis study with competitive agent tocilizumab fell short on its primary endpoint in modified Rodnan skin score, Piros tells investors in a research note partially titled "Lenabasum's Gain, Following Tocilizumab's Loss." The analyst believes the results establish Corbus' lenabasum, in Phase 3 now for systemic sclerosis, as the" only compelling treatment option for patients in this rare and life-threatening disease." Further, Additionally, Piros believes lenabasum's resolution of inflammatory activity was further validated in an assessment of interferon response in patients with dermatomyositis. The analyst reiterates an Overweight rating on the shares. Corbus Pharmaceuticals in afternoon trading is up 7.5c to $5.28.
09/10/18
09/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Inogen (INGN) downgraded to Buy from Strong Buy at Needham with analyst Mike Matson citing the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. 2. UnitedHealth (UNH) and Anthem (ANTM) were downgraded to Neutral from Buy at Citi. 3. Constellation Brands (STZ) downgraded to Hold from Buy at SunTrust with analyst William Chappell saying the company's recent $4B investment in Canopy Growth may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. 4. Darden (DRI) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing its recent strength and recommends a more disciplined approach to buying in the short-term as many restaurant names begin to look extended. 5. Roche (RHHBY) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
09/17/18
OPCO
09/17/18
NO CHANGE
Target $400
OPCO
Outperform
Roche's AD updates provide favorable read-through for Biogen, says Oppenheimer
Oppenheimer analyst Jay Olson says he remain bullish on Biogen (BIIB), telling investors in a research note that he believes Roche's (RHHBY) Alzheimer's disease updates provide a favorable read-through for Biogen's own Alzheimer's disease portfolio. Among the takeaways from Roche's pipeline update are the importance of a reduction in amyloid, confidence in dose escalation, epidemiology estimate and reimbursement commentary. Olson, who has an Outperform rating and $400 price target on Biogen, says he believes shares are undervalued based on his view that the company's leadership position in neuroscience should deliver long-term growth.
TKPYY Use TAK
$0.00

(0.00%)

09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
TMO Thermo Fisher
$243.18

1.03 (0.43%)

09/24/18
LEHM
09/24/18
NO CHANGE
Target $275
LEHM
Overweight
Thermo Fisher price target raised to $275 from $250 at Barclays
Barclays analyst Jack Meehan raised his price target for Thermo Fisher Scientific to $275 after hosting meetings with the company's management across Europe. The analyst says he believes, more so than ever, that Thermo Fisher's customer value proposition is resonating in the market. Further, following a period of major consolidation, Thermo's portfolio is tilting toward a faster growth trajectory, Meehan tells investors in a research note. He keeps an Overweight rating on the name.
07/26/18
JPMS
07/26/18
NO CHANGE
Target $300
JPMS
Overweight
Thermo Fisher price target raised to $300 from $250 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Thermo Fisher to $300 saying the company yesterday reported "yet another strong quarter, delivering beats on both the top and bottom lines." The analyst continues to like the setup for the stock with "healthy end markets, updated guidance still leaving room for beat-and-raises throughout the year, and a clear path to organic revenue acceleration in 2019 and beyond." He reiterates an Overweight rating on Thermo Fisher.
09/17/18
GSCO
09/17/18
DOWNGRADE
GSCO
Neutral
Thermo Fisher downgraded to Neutral from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly downgraded Thermo Fisher (TMO) to Neutral from Conviction Buy with an unchanged price target of $250. The analyst coupled the downgrade with an upgrade of Agilent Technologies (A) to Conviction Buy from Buy. The analyst believes his thesis on Thermo Fisher, centering around deal-driven accelerating growth and margin expansion, is more appropriately reflected in the current valuation. Further, the company faces a difficult set of comps starting in Q4 of this year, Donnelly tells investors in a research note. The analyst remains positive on Thermo Fisher's fundamentals, but prefers the set-up for Agilent at current valuation levels.
07/26/18
LEER
07/26/18
NO CHANGE
Target $255
LEER
Outperform
Thermo Fisher price target raised to $255 from $239 at Leerink
Leerink analyst Puneet Souda raised his price target for Thermo Fisher to $255 from $239 as an "impressive" quarter sets stage for higher growth profile ahead. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

SE

Sea Limited

$25.41

-0.39 (-1.51%)

14:49
05/21/19
05/21
14:49
05/21/19
14:49
Options
Sea Limited options imply 14.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

AAPL

Apple

$187.49

4.43 (2.42%)

14:31
05/21/19
05/21
14:31
05/21/19
14:31
Periodicals
Apple expands keyboard repair program to include butterfly mechanism, Verge says »

Apple is updating its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

CC

Chemours

$23.77

1.35 (6.02%)

14:30
05/21/19
05/21
14:30
05/21/19
14:30
Options
5K Chemours Oct 16 - 20 put spreads bought for 92c as shares rally »

5K Chemours Oct 16 - 20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
05/21/19
05/21
14:25
05/21/19
14:25
Conference/Events
Cowen biotechnology analysts to hold an analyst/industry conference call »

Biotechnology Analysts…

QRVO

Qorvo

$62.14

0.84 (1.37%)

14:22
05/21/19
05/21
14:22
05/21/19
14:22
Recommendations
Qorvo analyst commentary at Oppenheimer »

Qorvo could be first to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PED

PEDEVCO Corp.

$2.02

-0.06 (-2.88%)

14:21
05/21/19
05/21
14:21
05/21/19
14:21
Hot Stocks
PEDEVCO Corp. announces sale of stock to SK Energy, two unaffiliated investors »

PEDEVCO Corp. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PED

PEDEVCO Corp.

$2.02

-0.06 (-2.88%)

14:20
05/21/19
05/21
14:20
05/21/19
14:20
Hot Stocks
Breaking Hot Stocks news story on PEDEVCO Corp. »

PEDEVCO Corp. trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
05/21/19
05/21
14:17
05/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
05/21/19
05/21
14:16
05/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$127.09

0.9 (0.71%)

, AAPL

Apple

$187.52

4.46 (2.44%)

14:15
05/21/19
05/21
14:15
05/21/19
14:15
Periodicals
Microsoft cuts Huawei laptop from store, Verge says »

According to a story from…

MSFT

Microsoft

$127.09

0.9 (0.71%)

AAPL

Apple

$187.52

4.46 (2.44%)

HPQ

HP Inc.

$19.55

0.6 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

BCRX

BioCryst

$3.45

-3.95 (-53.38%)

14:13
05/21/19
05/21
14:13
05/21/19
14:13
Recommendations
BioCryst analyst commentary at JMP Securities »

BioCryst pullback an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

XRX

Xerox

$32.83

0.705 (2.19%)

14:12
05/21/19
05/21
14:12
05/21/19
14:12
Hot Stocks
Xerox shareholders approve holding company reorganization »

Xerox announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

YELP

Yelp

$32.36

0.65 (2.05%)

14:10
05/21/19
05/21
14:10
05/21/19
14:10
Options
Bullish option flow in Yelp »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 27

    Jun

PED

PEDEVCO Corp.

$2.02

-0.06 (-2.88%)

13:51
05/21/19
05/21
13:51
05/21/19
13:51
Hot Stocks
Breaking Hot Stocks news story on PEDEVCO Corp. »

PEDEVCO Corp. trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIR

Circor

$42.87

12.23 (39.92%)

13:47
05/21/19
05/21
13:47
05/21/19
13:47
Hot Stocks
Breaking Hot Stocks news story on Circor 

CIRCOR trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYDS

Payment Data Systems

$2.30

0.18 (8.49%)

13:46
05/21/19
05/21
13:46
05/21/19
13:46
Hot Stocks
Payment Data Systems jumps over 7% after announcing pact with Pineapple Payments »

Earlier on Tuesday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 30

    May

  • 11

    Jun

FLR

Fluor

$29.94

0.48 (1.63%)

13:45
05/21/19
05/21
13:45
05/21/19
13:45
Options
Fluor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

  • 13

    Jun

GOOD

Gladstone

$21.61

0.165 (0.77%)

13:41
05/21/19
05/21
13:41
05/21/19
13:41
Recommendations
Gladstone analyst commentary at Ladenburg »

Gladstone's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

CIR

Circor

$42.96

12.32 (40.21%)

, CR

Crane

$83.27

-1.62 (-1.91%)

13:33
05/21/19
05/21
13:33
05/21/19
13:33
Hot Stocks
Circor again rejects Crane bid, says it 'substantially' undervalues company »

Circor International…

CIR

Circor

$42.96

12.32 (40.21%)

CR

Crane

$83.27

-1.62 (-1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIR

Circor

$42.96

12.32 (40.21%)

, CR

Crane

$83.27

-1.62 (-1.91%)

13:30
05/21/19
05/21
13:30
05/21/19
13:30
Hot Stocks
Breaking Hot Stocks news story on Circor, Crane »

Circor 'reiterates…

CIR

Circor

$42.96

12.32 (40.21%)

CR

Crane

$83.27

-1.62 (-1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$48.03

0.52 (1.09%)

13:30
05/21/19
05/21
13:30
05/21/19
13:30
Periodicals
MetLife in talks to sell central European assets to Generali, Bloomberg says »

The business being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 18

    Jun

  • 18

    Jun

PXD

Pioneer Natural

$157.52

3.29 (2.13%)

13:26
05/21/19
05/21
13:26
05/21/19
13:26
Hot Stocks
Pioneer Natural backs Q2 Permian production view 313-328 MBOEPD »

Backs Q2 Permian oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 07

    Aug

CMCSA

Comcast

$43.15

0.37 (0.86%)

, CMCSK

Comcast

$0.00

(0.00%)

13:25
05/21/19
05/21
13:25
05/21/19
13:25
Periodicals
Comcast working on device similar to Amazon Echo, focused on health, CNBC says »

Comcast (CMCSA, CMCSK) is…

CMCSA

Comcast

$43.15

0.37 (0.86%)

CMCSK

Comcast

$0.00

(0.00%)

AMZN

Amazon.com

$1,853.86

-4.95 (-0.27%)

GOOG

Alphabet

$1,151.98

13.65 (1.20%)

GOOGL

Alphabet Class A

$1,157.99

12.71 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 03

    Jun

  • 05

    Jun

  • 19

    Jun

  • 19

    Jun

  • 24

    Jun

  • 27

    Oct

CIR

Circor

$43.01

12.37 (40.37%)

13:25
05/21/19
05/21
13:25
05/21/19
13:25
Hot Stocks
Breaking Hot Stocks news story on Circor »

CIRCOR trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PXD

Pioneer Natural

$157.52

3.29 (2.13%)

13:25
05/21/19
05/21
13:25
05/21/19
13:25
Hot Stocks
Pioneer Natural sees FY19 Permian production 320-335 MBOEPD »

Sees FY19 cash flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.